No black box warning on record for Aqvesme

As of the latest FDA labeling reviewed, Aqvesme (MITAPIVAT) does not carry a black box warning. Standard warnings and precautions still apply — see the full Aqvesme medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Hepatocellular Injury AQVESME can cause hepatocellular injury. Avoid use of AQVESME in patients with cirrhosis. In patients with thalassemia treated with AQVESME, liver injury with and without jaundice has been observed within the first 6 months of exposure. Obtain liver tests (including ALT, AST, alkaline phosphatase, total bilirubin with fractionation) prior to the

No black box warning on record for Aqvesme

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS 5.1 Hepatocellular Injury AQVESME can cause hepatocellular injury. Avoid use of AQVESME in patients with cirrhosis. In patients with thalassemia treated with AQVESME, liver injury with and without jaundice has been observed within the first 6 months of exposure. Obtain liver tests (including ALT, AST, alkaline phosphatase, total bilirubin with fractionation) prior to the

Aqvesme Black Box Warning

No black box warning on record for Aqvesme

Other warnings & precautions

Aqvesme Black Box Warning

No black box warning on record for Aqvesme

Other warnings & precautions